Friday,December 8, 1995 8Th Annual San Antonio flow cytometry forum |
| |
| Authors: | Ira Pastan Lee H Pai Ulrich Brinkmann David FitzGerald |
| |
| Institution: | (1) Laboratory of Molecular Biology, Division of Cancer Biology, Diagnosis and Centers, National Cancer Institute, National Institutes of Health, 37 Convent Drive, MSC 4255 Bethesda, MD, USA |
| |
| Abstract: | Summary
Pseudomonas exotoxin has been genetically modified so that it targets cancer cells. This was accomplished by deleting its cell binding domain and replacing it with Fv fragments of antibodies that react with breast, colon, and other cancers. Several recombinant immunotoxins are now in clinical trials.Presented at the symposium "New Approaches in the Therapy of Breast Cancer", Georgetown University Medical Center, Washington DC, October 1994, generously supported by an education grant from Bristol-Myers Squibb. |
| |
| Keywords: | breast cancer cancer treatment colon cancer Pseudomonas exotoxin |
| 本文献已被 SpringerLink 等数据库收录！ |
|
